Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone

Philip, P. A.; Carmichael, J.; Tonkin, Katia; Buamah, Paul K.; Britton, J. L.; Dowsett, Mitchell; Harris, Adrian L.

doi:10.1038/bjc.1993.69

Cited by 20 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This trial reported a median survival of 226 vs. 120 days in the flutamide and placebo groups, respectively ( p = 0.079, Wilcoxon; p = 0.01, log-rank). Several other studies in patients with pancreatic cancer have not shown hormonal therapies to be beneficial, however [ 116 , 117 , 118 , 119 , 120 , 121 ].…”

Section: Other Tumor Typesmentioning

confidence: 99%

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond

Schweizer

2017

Cancers

View full text Add to dashboard Cite

In the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past couple of decades, our understanding of AR-signaling biology has dramatically improved, and it has become apparent that the AR can modulate a number of other well-described oncogenic signaling pathways. Not surprisingly, mounting preclinical and epidemiologic data now supports a role for AR-signaling in promoting the growth and progression of several cancers other than prostate, and early phase clinical trials have documented preliminary signs of efficacy when AR-signaling inhibitors are used in several of these malignancies. In this article, we provide an overview of the evidence supporting the use of AR-directed therapies in prostate as well as other cancers, with an emphasis on the rationale for targeting AR-signaling across tumor types.

show abstract

Section: Other Tumor Typesmentioning

confidence: 99%

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond

Schweizer

2017

Cancers

View full text Add to dashboard Cite

show abstract

“…Despite the positive trial of flutamide for PaCa therapy [6], other small phase 2 trials have failed to show an obvious benefit to flutamide alone [28,29]. Similarly, there has been a lack of response or survival benefit in trials of flutamide in combination with gemcitabine [30], the AR inhibitor cyproterone acetate alone [31], the LHRH agonist goserelin alone [32], or LHRH agonist buserelin together with cyproterone acetate [33].…”

Section: Discussionmentioning

confidence: 95%

Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer

Konduri

Schwarz

Cafasso

et al. 2007

Journal of Surgical Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Philip et al (1993) treated 18 patients with an LHRH agonist in a phase II study. Serial measurements of CA19-9 showed a steady rise in serum concentrations in all patients, however none had a radiological response and only two patients had stabilization of the disease (Philip et al, 1993). In a study in which 82 patients with unresectable carcinoma of the pancreas were treated with tamoxifen, it was shown that, in patients who had a pretreatment CA19-9 level greater than 37 u ml-', a prolonged survival was observed in those who had a reduction or plateau compared with patients in whom the pretreatment CA19-9 level was less than 37 u ml-and who experienced a serial rise in the tumour marker (Wong and Chan, 1995).…”

Section: Discussionmentioning

confidence: 99%

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

Gogas

Lofts²,

Evans³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary Thirty-nine patients with inoperable adenocarcinoma of the pancreas were studied (27 male, 12 female; median age 60 years, range 39-75 years). All patients received chemotherapy with continuous infusion 5-fluorouracil with intravenous bolus epirubicin followed by cisplatin, repeated every 21 days for a total of six cycles and were evaluable for response. Serum CAl 9-9 concentrations were obtained at baseline and before each cycle. A rise or fall in the tumour marker was defined as a greater than 15% increase or decrease in the marker on two consecutive occasions 3 weeks apart. A plateau in the tumour marker was defined as a less than 15% decrease or increase on two occasions. Changes in marker expression were compared with serial computerized tomography scanning before treatment and after the third and sixth cycle of chemotherapy. Thirty-five of 39 patients had an elevated CA19-9 (87.9%). Thirteen (36.2%) exhibited a decrease, seven (19.4%) a plateau and 16 (44.4%) patients had a progressive rise in serum CAl 9-9. The sensitivity of CAl 9-9 was 67% for predicting a partial response and 86% for progressive disease. The median survival for the 13 patients exhibiting a reduction was 333 days, for the seven patients exhibiting a plateau 253 days and for those who had a progressive rise 185 days. The difference in median survival between the group of patients with > 15% decrease and those with > 15% increase of CAl 9-9 was significant (P = 0.001). In the cohort of patients who exhibited a reduction in CAl 9-9, no tumour progression was seen, and the reduction occurred during the first three cycles of treatment. Thus, interval scanning may be avoided in this group of patients.

show abstract

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone

Cited by 20 publications

References 18 publications

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond

Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

Contact Info

Product

Resources

About